ABBV: Dividend Aristocrat With Hidden Earnings
AbbVie Inc. (NYSE: ABBV) closed at $232.03 on February 28, 2026, up 3.27% on the session and commanding a market capitalization of $410.1 billion. The stock has rallied 41% from its 52-week low of $164.39 and now trades just 5% below its 52-week high of $244.81, comfortably above both its 50-day moving average of $224.13 and 200-day moving average of $212.09. The headline that stops most investors cold is the trailing P/E ratio of 98.7x. On its face, that looks absurd for a mature pharmaceutical company. But the GAAP earnings figure driving that ratio — just $2.35 per share over the trailing twelve months — is distorted by billions in non-cash amortization from AbbVie's $63 billion Allergan acquisition in 2020. Adjusted earnings tell a radically different story, and analyst estimates for 2027 suggest the gap between reported and economic earnings is about to narrow sharply. Q4 2025 revenue of $16.618 billion marked the strongest quarter in company history, capping a full year at approximately $61.16 billion. With Rinvoq and Skyrizi now firmly replacing lost Humira revenue, AbbVie has earned recognition as both a Dividend Aristocrat and, increasingly, a value stock hiding in plain sight behind acquisition accounting.